148 related articles for article (PubMed ID: 11770373)
1. [Lowering blood pressure in obese hypertensive patients. Which antihypertensive drugs are suitable].
Pischon T; Sharma AM
MMW Fortschr Med; 2001 Nov; 143(48):34-8. PubMed ID: 11770373
[TBL] [Abstract][Full Text] [Related]
2. Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper.
Doggrell SA
Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):119-25. PubMed ID: 15834464
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of antihypertensive therapy.
Grossman E; Messerli FH
Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
[TBL] [Abstract][Full Text] [Related]
4. [Antihypertensive treatment for patients with hypertension and diabetes type II--current clinical research].
Rajzer M; Kawecka-Jaszcz K; Wojciechowska W
Przegl Lek; 2003; 60(2):111-5. PubMed ID: 12939858
[TBL] [Abstract][Full Text] [Related]
5. Choice of antihypertensive drug in the diabetic patient.
Ong HT; Cheah JS
MedGenMed; 2005 May; 7(2):74. PubMed ID: 16369452
[TBL] [Abstract][Full Text] [Related]
6. Current recommendations for the treatment of hypertension: are they still valid?
Moser M
J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
[TBL] [Abstract][Full Text] [Related]
7. [Antihypertensive drug utilization in obese patients].
Bramlage P; Bramlage C; Kirch W
Med Klin (Munich); 2005 Dec; 100(12):804-9. PubMed ID: 16453095
[TBL] [Abstract][Full Text] [Related]
8. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
[TBL] [Abstract][Full Text] [Related]
9. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Sharma AM; Wagner T; Marsalek P
J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic implications of recent megatrials in hypertension: in favor of new drugs.
Volpe M; Tocci G
J Nephrol; 2007; 20 Suppl 12():S12-8. PubMed ID: 18050137
[TBL] [Abstract][Full Text] [Related]
11. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
12. Seeking the ideal anti-hypertensive agent: a practical review of the hypertension drug trials.
Ong HT; Cheah JS
N Z Med J; 2004 Feb; 117(1189):U773. PubMed ID: 15014562
[TBL] [Abstract][Full Text] [Related]
13. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
14. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
15. The metabolic syndrome in hypertension: European society of hypertension position statement.
Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
[TBL] [Abstract][Full Text] [Related]
16. Obesity-related hypertension: its physiological basis and pharmacological approaches to its treatment.
Richards RJ; Thakur V; Reisin E
J Hum Hypertens; 1996 Sep; 10 Suppl 3():S59-64. PubMed ID: 8872829
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
de Boer RA; van Veldhuisen DJ; Gans RO; Gansevoort RT
Ned Tijdschr Geneeskd; 2003 Jan; 147(3):96-9. PubMed ID: 12577767
[TBL] [Abstract][Full Text] [Related]
18. Thiazide diuretics in the treatment of hypertension: an update.
Salvetti A; Ghiadoni L
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S25-9. PubMed ID: 16565243
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome: treatment of hypertensive patients.
Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
